Work

1 Oral: First Clinical Results from A Phase 1 Trial of PRT3789, a First-in-Class Intravenous SMARCA2 Degrader, in Patients with Advanced Solid Tumors with a SMARCA4 Mutation

Year: 2024

Type: article

Source: European Journal of Cancer

DOI: 10.1016/j.ejca.2024.114530

Authors: T.A. Yap, A. Dowlati, I. Dagogo-Jack, J. Vibert, A.I. Spira, V. Moreno Garcia, S.R. Punekar, E. Calvo, G.P. Sonpavde, M. Awad, J.W. Riess, T. Hernández-Guerrero, B. Herzberg, A. Italiano, A. Swalduz, P. LoRusso, E.F. Smit, E.B. Garon, W. Novotny, R. Guo

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4403764153

FWCI: 0.116

Cites:

Cited by: 1

Related to: 10